Ana Carolina Amorim Oliveira, Ana Paula Amorim Oliveira, Ana Paula Macedo Prudente de Queiroz, Danielle Alves Barreto, Julianne Alves Machado.Universidade Tiradentes (UNIT), Aracaju - SE.Publicado no Caderno de Anais de Evento | DOI: https://doi.org/10.25248/anais.e6674.2021.Referências: HIGASHI N, et al. Advances in aspirin-exacerbated respiratory disease (AERD). Nihon Rinsho. 2016;74(10):1683-1687. JERSCHOW E, et al. Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbado Respiratory Disease. J Alergia Clin Immunol Pract. 2017;5(4):998-1007.e2. LI KL, et al. Aspirina Exacerbada Doença Respiratória: Epidemiologia, Fisiopatologia e Gestão. Med Sci (Basileia). 2019;7(3):45. RODRÍGUEZ-JIMÉNEZ JC, et al. Aspirin exacerbated respiratory disease: Current topics and trends. Respir Med. 2018; TANIGUCHI N, et al, Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD. Allergol Int. 2019; 68(3):289-295